ECA combines ephedrine, caffeine, and optional aspirin to modestly boost calorie burning and curb appetite for short-term fat loss, shifting weight lost toward fat over muscle. Benefits are smaller in already-lean adults, while stimulant effects — faster heart rate, palpitations, anxiety, insomnia, stomach upset — persist, alongside a rare risk of serious heart and stroke events. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | ~110–125 / 70–80 mmHg | Ephedrine raises blood pressure; the key safety signal |
| Resting heart rate | 55–70 beats/min | Detects excess sympathetic stimulation |
| Fasting glucose | 75–90 mg/dL | Stimulants can transiently raise glucose/insulin resistance |
| Lipid panel (HDL, LDL, triglycerides) | HDL >55; LDL <100; TG <90 mg/dL | Tracks metabolic response and the possible lipid benefit |
| Thyroid-stimulating hormone (TSH) | 0.5–2.5 mIU/L | Screens for hyperthyroidism, a contraindication, before and during use |
| Electrocardiogram (ECG) | Normal sinus rhythm | Screens for arrhythmia or ischemia in at-risk users |
Cadence: Baseline before first dose; blood pressure and resting heart rate at week 1, weeks 2–4, then every 4–8 weeks; glucose, lipids, and thyroid function every 3–6 months during extended use.